Showing posts with label
Big Pharma
.
Show all posts
Showing posts with label
Big Pharma
.
Show all posts
Wednesday, September 22, 2021
FDA to PTO
Here
.
Monday, May 10, 2021
Essays on the Economics of the Pharmaceutical Industry
M. Newham,
here
.
Monday, September 30, 2019
The industry that cries wolf: pharma and innovation
M. Carrier, G. Tung,
here
.
Wednesday, February 27, 2019
US drugmakers defend pricing under fire in Senate
FT,
here
.
Tuesday, December 18, 2018
Warren bill would get feds into generic drug manufacturing
Politico,
here
.
Older Posts
Home
Subscribe to:
Posts (Atom)
Guelphs and Ghibellines, 102 Brussels Edition (a View from the Digital Ciompi)
Not Tagliacozzo, but Florence (IBA Annual Conference) The Guelphs : the less conservative academics defending the Commission’s 102 Guidelin...
How to Fix a Failing Art. 102 TFEU: Substantive Interpretation, Evidentiary Requirements, and the Commission's Future Guidelines on Exclusionary Abuses
H. Schweitzer, S. de Ridder, here (and here ).
"German" Apple ATTF
Here .
Study on the impact of mergers reviewed by the Commission on innovation and markups
EC, here.
GC confirms: Edge not a DMA gatekeeper (?)
GC, here .
CASE DMA.100193 - Alphabet - Online Search Engine - Google Search - Art. 6(5)
Here .
Guidelines on the application of Article 102 of the Treaty on the Functioning of the European Union to abusive exclusionary conduct by dominant undertakings
EC, here . Useful here.
‘Digital Public Infrastructure’: Cultural hegemony and states’ technological dependence
C. Rikap, here.
Agentic AI: Technical Developments, Potential Impact on Consumers and Markets, and Regulatory Implications
B. Jansen et al., here .
Economic study on dynamic effects of mergers
EC, here.
.jpg)
Not Tagliacozzo, but Florence (IBA Annual Conference) The Guelphs : the less conservative academics defending the Commission’s 102 Guidelin...